Nuvalent 2024 Company Overview - NUVL Investor Presentation

Nuvalent is a clinical-stage biopharmaceutical company developing targeted therapies for non-small cell lung cancer with parallel lead programs for ROS1+ and ALK+ NSCLC. The presentation outlines the company's OnTarget 2026 operating plan, clinical pipeline including zidesamtinib and other candidates, and cash runway extending into 2027.